JUPITER NEUROSCIENCES, INC. (JUNS)
About JUPITER NEUROSCIENCES, INC.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $21.8K
- Net income
- -$8.6M
- Total assets
- $5.6M
- Market cap
- $10.5M
- Operating margin
- -40873.2%
- Net margin
- -39662.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $21.8K
- Operating expenses
- $8.9M
- Operating income
- -$8.9M
- Net income
- -$8.6M
- EPS (basic)
- $-0.25
- EPS (diluted)
- $-0.25
Balance sheet
- Total assets
- $5.6M
- Current assets
- $4.8M
- Total liabilities
- $7.4M
- Current liabilities
- $7.4M
- Shareholders’ equity
- -$1.8M
Cash flow
- Operating cash flow
- -$5.4M
- Investing cash flow
- -$19.8K
- Financing cash flow
- $5.4M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.5M
- EPS (diluted)
- $-0.25
- Shares outstanding
- 87.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 3, 2024
Jupiter Neurosciences, Inc. (JUNS) Stock Price
- Reported a net loss of $8.6M in FY2025.
- Trading 96% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review JUPITER NEUROSCIENCES, INC..
Write a review
News about JUPITER NEUROSCIENCES, INC.
News & sentiment via Polygon.io
Jupiter Neurosciences, Inc.: frequently asked questions
Is Jupiter Neurosciences, Inc. an American company?
Jupiter Neurosciences, Inc. is a US-based company headquartered in Jupiter, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Jupiter Neurosciences, Inc. headquartered?
Jupiter Neurosciences, Inc. is headquartered in Jupiter, Florida, United States.
Is Jupiter Neurosciences, Inc. publicly traded?
Yes — Jupiter Neurosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol JUNS on the NASDAQ.
What does Jupiter Neurosciences, Inc. do?
Jupiter Neurosciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
